Ken Griffin Sio Gene Therapies Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.28 - $0.44 $4,256 - $6,688	15,202 New	15,202 $6,000
Q1 2022 May 16, 2022	BUY	$0.55 - $1.47 $40,180 - $107,390	73,055 Added 54.11%	208,065 $139,000
Q4 2021 Feb 14, 2022	BUY	$1.29 - $2.36 $98,646 - $180,469	76,470 Added 130.63%	135,010 $174,000
Q3 2021 Nov 15, 2021	BUY	$1.81 - $2.7 $24,509 - $36,560	13,541 Added 30.09%	58,540 $127,000
Q2 2021 Aug 16, 2021	BUY	$2.07 - $2.89 $27,545 - $38,457	13,307 Added 41.99%	44,999 $122,000
Q1 2021 May 17, 2021	SELL	$2.34 - $3.44 $85,969 - $126,382	-36,739 Reduced 53.69%	31,692 $83,000
Q4 2020 Feb 16, 2021	BUY	$1.91 - $5.63 $130,703 - $385,266	68,431 New	68,431 $190,000

147K

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.